Clinical pilot study of ultrasound cyclocoagulation shows safety and efficacy in refractory glaucoma

Results from a phase 1 pilot study investigating the use of high intensity focused ultrasound (“HIFU”) have shown both safety and efficacy in patients with refractory glaucoma. The clinical research, led by the Hopital Edouard Herriot in Lyon and supported by the company EyeTech Care, showed that patients benefited from a significant (P<0.01) reduction of almost 36% three months after the treatment. The 12-month three-centre prospective interventional study on 12 patients showed a reduction in intraocular pressure (IOP) from a mean preoperative value of 37.9±10.7 mm Hg to a mean postoperative value of 27.3±12.4, 25.2±11.3, 25.2±7.7, 24.8±9.8, and 26.3±5.1 mm Hg at 1 day, 1 week, 1 month, 3 months, and 6 months, respectively, and to a mean value of 24.7±8.5 at the last follow-up visit.